213013-98-0

Usage

Uses

Used in Pharmaceutical Research:
1-tert-Butyl 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate is used as a research compound for the development of new pharmaceuticals. Its unique structure, including the piperidine ring and various substituents, makes it a valuable candidate for exploring its potential medicinal properties and applications in drug discovery.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-tert-Butyl 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate is utilized as a building block or intermediate in the synthesis of various bioactive molecules. Its presence of functional groups, such as the carboxylate groups, allows for further chemical modifications and the creation of new compounds with potential therapeutic effects.
Used in Drug Design and Development:
1-tert-Butyl 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate is employed as a key component in drug design and development processes. Its structural features and potential reactivity make it a promising candidate for the creation of novel therapeutic agents, particularly in the areas of central nervous system disorders, cardiovascular diseases, and other medical conditions that may benefit from piperidine-based compounds.

Upstream product

• 75-11-6 diiodomethane 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4111-54-0 lithium diisopropyl amide 
• 77-92-9 citric acid 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 213014-17-6 4-[4-(3,4-dimethyl-phenoxy)-phenylsulfanylmethyl]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 213014-03-0 4-(4-phenoxy-phenylsulfanylmethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 946857-73-4 4-(4-hydroxy-phenylsulfanylmethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 287202-23-7 1-(tert-butyl) 4-ethyl 4-({[4-(2-butynyloxy)phenyl]sulfanyl}methyl)-1,4-piperidinedicarboxylate 

Relevant academic research and scientific papers

Structure-based design of TACE selective inhibitors: Manipulations in the S1′-S3′ pocket

A series of β-sulfonyl hydroxamate TACE inhibitors, bearing a butynylamino or a butynyloxy P1′ group, was designed and synthesized. Of the compounds investigated, 22 has excellent potency against isolated TACE enzyme, shows good selectivity over MMP-2 and

Identification of potent and selective TACE inhibitors via the S1 pocket

By focusing on the P1 portion of the piperidine β-sulfone ligands we identified a motif that induces selectivity and resulted in a series of TACE inhibitors that demonstrated excellent in vitro potency against isolated TACE enzyme and excellent selectivity over MMPs 1, 2, 9, 13, and 14.

Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors

Structure-based methods were used to design β-sulfone 3,3-piperidine hydroxamates as TACE inhibitors with the aim of improving selectivity for TACE versus MMP-13. Several compounds in this series were synthesized and evaluated in enzymatic and cell-based

Design and synthesis of butynyloxyphenyl β-sulfone piperidine hydroxamates as TACE inhibitors

A series of butynyloxyphenyl β-sulfone piperidine hydroxamate TACE inhibitors was designed and synthesized. The resulting structure-activity relationship and MMP selectivity of the series were examined. Of the compounds investigated, 17s has excellent in

Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy

α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone h

ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS

Compounds of the formula:useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring

A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds 1 and 2 exhibited potent inhibitory activity against factor Xa (FXa) and good selectivity with respect to other serine

Amidine compounds

A compound of the formula [I] wherein R1, R2and R3are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the presen

Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors

Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.